The pending deal was rumored overnight after a report from the Financial Times, spurring analysts to speculate that if true, ...

The latest clinical win follows a dual set of phase 3 and phase 2 results back in March. In that data drop, Mineralys reported that lorundrostat reduced systolic blood pressure in a late-stage study ...

Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to US$1.3 billion to boost its pipeline beyond its blockbuster weight-loss and diabetes drugs.

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization in US infants.